Tandem Diabetes Care Stock Analysis

Tandem Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 494.25. Tandem Diabetes Care recorded a loss per share of 3.43. The entity last dividend was issued on the 10th of October 2017. The firm had 1:10 split on the 10th of October 2017. Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. To find out more about Tandem Diabetes Care contact Kim Blickenstaff at 858 366 6900 or learn more at https://www.tandemdiabetes.com.

Tandem Diabetes Care Investment Alerts

Tandem Diabetes Care Upcoming and Recent Events

Tandem Largest EPS Surprises

View All Earnings Estimates

Tandem Diabetes Thematic Classifications

Tandem Stock Institutional Investors

Note, although Tandem Diabetes' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tandem Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tandem Diabetes's market, we take the total number of its shares issued and multiply it by Tandem Diabetes's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Tandem Profitablity

The company has Profit Margin (PM) of (0.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.18.

Management Efficiency

Tandem Diabetes Care has return on total asset (ROA) of (0.0963) % which means that it has lost $0.0963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of April 2024, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.29. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 20th of April 2024, Net Tangible Assets is likely to grow to about 531.2 M, while Intangibles To Total Assets are likely to drop 0.

Technical Drivers

As of the 20th of April, Tandem Diabetes has the Coefficient Of Variation of 1043.1, semi deviation of 3.44, and Risk Adjusted Performance of 0.0674. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tandem Diabetes Care, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down nineteen technical drivers for Tandem Diabetes Care, which can be compared to its competition. Please validate Tandem Diabetes Care variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Tandem Diabetes is priced more or less accurately, providing market reflects its prevalent price of 30.43 per share. Given that Tandem Diabetes Care has jensen alpha of 0.2872, we advise you to double-check Tandem Diabetes Care's current market performance to make sure the company can sustain itself at a future point.

Tandem Diabetes Care Price Movement Analysis

Tandem Diabetes Care Insider Trading Activities

Tandem Diabetes Predictive Daily Indicators

Tandem Diabetes Corporate Filings

Tandem Diabetes Forecast Models

Tandem Diabetes' time-series forecasting models are one of many Tandem Diabetes' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tandem Diabetes' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tandem Diabetes prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tandem shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tandem Diabetes. By using and applying Tandem Stock analysis, traders can create a robust methodology for identifying Tandem entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tandem analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tandem analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Tandem Diabetes Care stock analysis indicators help investors evaluate how Tandem Diabetes stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tandem Diabetes shares will generate the highest return on investment. By understating and applying Tandem Diabetes stock analysis, traders can identify Tandem Diabetes position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.

Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.